Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Chet Metcalf

Vice President & Head, R&D Chemistry Regeneron Pharmaceuticals

Seminars

Monday 12th October 2026

Summary Panel Discussion: Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation

3:00 pm

At the end of the seminar day, don’t miss this summary panel discussion to discuss, debate and challenge your speakers and ADC peers on the cutting-edge of ADC design, exploring the most promising areas of ADC innovation, benefits against traditional therapies, and hurdles to advance novel conjugates into and through the clinic.

Monday 12th October 2026

Pushing the Boundary of Novel Bioconjugate Mechanisms & Design